Amicus abandons wound treatment, focus shifts to future trial data

(Reuters) - Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline.

Amicus abandons wound treatment, focus shifts to future trial data

(Reuters) - Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors ...

Wed 13 Sep 17 from Reuters

Amicus to abandon wound treatment after late-stage failure

(Reuters) - U.S. drug developer Amicus Therapeutics Inc said on Wednesday it would no longer invest in clinical trials of its drug for healing wounds after the experimental treatment failed ...

Wed 13 Sep 17 from Reuters

Amicus to abandon wound treatment after it fails late-stage trial

(Reuters) - U.S. drug developer Amicus Therapeutics Inc said on Wednesday it will not invest in any more clinical trials of its drug to heal wounds, after the experimental treatment failed to ...

Wed 13 Sep 17 from Reuters

Amicus Therapeutics' wound treatment fails late-stage trial

(Reuters) - U.S. drug developer Amicus Therapeutics Inc said on Wednesday its drug to treat wounds failed to meet the main goals of a late-stage clinical trial.

Wed 13 Sep 17 from Reuters

  • Pages: 1

Bookmark

Bookmark and Share